evidence table
Magnesium Stress Randomized Trial Evidence Table
Structured evidence table for Magnesium Stress Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Magnesium Stress Randomized Trial | Epidemiological data consistently demonstrate that low dietary Mg intake and low serum Mg are independently associated with hypertension, coronary artery calcification, peripheral arterial disease (PAD), stroke, and cardiovascular mortality [,]. | 4 | Yoon Yonghyun (2026) | Magnesium at the Neurovascular Interface: A Narrative Review of Atherosclerosis, Peripheral Arterial Disease, and Neuropathic Pain |
| Magnesium Stress Randomized Trial | Based on these criteria and the conceptual scope of this narrative review, the most relevant mechanistic, translational, epidemiological, clinical, guideline, and nutritional reference sources were incorporated into the final narrative synthesis. | 4 | Yoon Yonghyun (2026) | Magnesium at the Neurovascular Interface: A Narrative Review of Atherosclerosis, Peripheral Arterial Disease, and Neuropathic Pain |
| Magnesium Stress Randomized Trial | Instead, it focuses on selected evidence relevant to the neurovascular consequences of low magnesium status and its potential contribution to overlapping ischemic and neuropathic pain phenotypes. | 4 | Yoon Yonghyun (2026) | Magnesium at the Neurovascular Interface: A Narrative Review of Atherosclerosis, Peripheral Arterial Disease, and Neuropathic Pain |
| Magnesium Stress Randomized Trial | 1 2 3 4 Magnesium (Mg) is the fourth most abundant mineral in the human body and the second most prevalent intracellular cation after potassium, functioning as a cofactor in over 600 enzymatic systems governing energy metabolism, nucleic acid synthesis, ion channel regulation, and neurotransmitter release [,]. | 4 | Yoon Yonghyun (2026) | Magnesium at the Neurovascular Interface: A Narrative Review of Atherosclerosis, Peripheral Arterial Disease, and Neuropathic Pain |
| Magnesium Stress Randomized Trial | Failure to meet the recommended 7-9 hours of restful sleep per night is known to increase the risk of several health conditions, reason why regular and adequate sleep should be seen as a priority instead of an unnecessary commodity easily traded as required by the commitments of our busy lives. | 4 | Conti F (2026) | Dietary Protocols to Promote and Improve Restful Sleep: A Narrative Review. |
| Magnesium Stress Randomized Trial | While both the quantity and the quality of sleep can be largely improved with relatively straightforward practices dictated by good sleep hygiene, emerging research suggests that dietary and supplementation protocols focused on certain foods, nutrients, and biochemical compounds with sleep-promoting properties can act as subsidiary sleep aids in complementing these behavioral changes. | 4 | Conti F (2026) | Dietary Protocols to Promote and Improve Restful Sleep: A Narrative Review. |
| Magnesium Stress Randomized Trial | The scope of this narrative review is to summarize the available evidence on the potential benefits of selected nutraceuticals in the context of circadian rhythm and sleep disturbances, namely melatonin, magnesium, omega-3 fatty acids, tart cherry juice, kiwifruit, apigenin, valerian root, L-theanine, glycine, ashwagandha, myoinositol, Rhodiola rosea, and phosphatidylserine. | 4 | Conti F (2026) | Dietary Protocols to Promote and Improve Restful Sleep: A Narrative Review. |
| Magnesium Stress Randomized Trial | Humans spend approximately one third of their life asleep but, as counterintuitive as it may sound, sleep is far from being a quiet state of inactivity. | 4 | Conti F (2026) | Dietary Protocols to Promote and Improve Restful Sleep: A Narrative Review. |
Source documents